{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T16:29:38Z","timestamp":1748968178092,"version":"3.41.0"},"reference-count":0,"publisher":"International Institute of Anticancer Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CDP"],"published-print":{"date-parts":[[2025,5,3]]},"abstract":"<jats:p>Background\/Aim:\nThis study analyzed prognostic factors in patients with lung adenocarcinoma and bone metastases who tested positive for epidermal growth factor receptor (EGFR) mutations.\nPatients and Methods:\nWe retrospectively reviewed the records of 117 patients with lung adenocarcinoma and bone metastases who were followed up at a single institution for 0.2 months to 66 months. Of these 117 patients, 45 were EGFR mutation-positive and further analysis was performed for these patients. Median survival times and five-year survival rates were investigated according to performance status (PS), oligometastatic status, radiotherapy and EGFR-tyrosine kinase inhibitor (TKI) administration.\nResults:\nThe five-year survival rate of EGFR mutation-positive patients was 9.2%, and median survival time was 22.7 months; their mean age was 69.5 years. Many EGFR mutation-positive patients had a PS of 2, and the median survival time showed significant differences according to PS (0\/1\/2 vs. 3\/4) and oligometastatic status.\nConclusion:\nAlthough there was no difference in the mean survival time between patients receiving or not receiving bone radiotherapy, the treatment effectively reduced pain and prevented paralysis. As a first-line treatment in EGFR mutation-positive patients, first- or second-generation TKIs followed by third-generation TKIs showed favorable outcomes.<\/jats:p>","DOI":"10.21873\/cdp.10451","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T13:22:31Z","timestamp":1746624151000},"page":"386-395","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Factors in EGFR Mutation\u2010positive Patients With Bone Metastases from Lung Adenocarcinoma"],"prefix":"10.21873","volume":"5","author":[{"given":"SHUNZO","family":"OSAKA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JUNZO","family":"KAWASHIMA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RYOMA","family":"KAGUCHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NAOKI","family":"TODA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AKIRA","family":"KISOHARA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHUMEI","family":"KAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KOHEI","family":"TAGAWA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TOSHIO","family":"KOJIMA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TAKAKO","family":"NAGAI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EIJI","family":"OSAKA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KAZUYOSHI","family":"NAKANISHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YOSHIAKI","family":"TANAKA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"9336","published-online":{"date-parts":[[2025,5,3]]},"container-title":["Cancer Diagnosis &amp; Prognosis"],"original-title":[],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T13:22:35Z","timestamp":1746624155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cancerdiagnosisprognosis.org\/article\/505\/prognostic-factors-in-egfr-mutationpositive-patients-with-bone-metastases-from-lung-adenocarcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,5,3]]},"published-print":{"date-parts":[[2025,5,3]]}},"URL":"https:\/\/doi.org\/10.21873\/cdp.10451","relation":{},"ISSN":["2732-7787"],"issn-type":[{"type":"print","value":"2732-7787"}],"subject":[],"published":{"date-parts":[[2025,5,3]]}}}